Skip to main content

Cardiac Output, Low

2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
2
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Orion Pharma
Orion PharmaUK - Reading
1 program
1
LevosimendanPhase 2/31 trial
Active Trials
NCT04179604Unknown300Est. Dec 2022
Orion
OrionUK - Cambridge
1 program
1
LevosimendanPhase 2/3
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Changes in Cardiac Output During Delayed Umbilical Cord ClampingN/A1 trial
Active Trials
NCT02195037Completed20Est. Dec 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Orion PharmaLevosimendan
Sharp TherapeuticsChanges in Cardiac Output During Delayed Umbilical Cord Clamping

Clinical Trials (2)

Total enrollment: 320 patients across 2 trials

Spanish Randomized Clinical Trial to Compare Levosimendan Versus Placebo in Postoperative Cardiac Surgery (SPARTANS)

Start: Jun 2020Est. completion: Dec 2022300 patients
Phase 2/3Unknown
NCT02195037Sharp TherapeuticsChanges in Cardiac Output During Delayed Umbilical Cord Clamping

Changes in Cardiac Output During Delayed Umbilical Cord Clamping

Start: Jul 2014Est. completion: Dec 201420 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.